Loading…
Major Chinese private eye-hospital chain providing cataract surgery, refractive (LASIK) surgery and other ophthalmology services.
Major Chinese private eye-hospital chain providing cataract surgery, refractive (LASIK) surgery and other ophthalmology services.
Mostly paid directly by patients for elective surgery such as LASIK, so demand depends on household spending rather than insurance, while cataract surgery, partly covered by public health insurance, gives a more routine flow. Premium lenses and optical goods raise the amount spent per patient.
In one line: A Chinese private eye-hospital chain, akin to a scaled LASIK/eye-care network.
Moat: narrow (brand, scale, regulatory licence). Scaled hospital network and licensed ophthalmologist base versus smaller regional clinics.
Headquarters: Xiamen, China · Employees: 8,200
Size Huaxia Eye Hospital (301267.SZ) is a China Health Care company (Hospital/Nursing Management) with a market value of $1.92B, the 1310th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.31 on 6 Nov 2026.
Performance Over six months the shares fell 15.8%, against +2.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +6.9%); the operating margin is 14.9% (peer median 8.8%).
Valuation It trades at 24.7× forward earnings against a peer median of 38.1× (6th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.5 points above its cost of capital (9.6% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.21B | CN¥4.13B | CN¥4.02B | CN¥4.01B | CN¥3.23B |
| Revenue growth | — | +3% | 0% | +24% | — |
| Gross profit | CN¥2.03B | CN¥1.68B | CN¥1.67B | CN¥1.87B | CN¥1.47B |
| EBITDA | n/a | CN¥1.01B | CN¥972M | CN¥1.21B | CN¥1.05B |
| Net income | CN¥473M | CN¥441M | CN¥429M | CN¥666M | CN¥514M |
| Free cash flow | CN¥784M | CN¥697M | CN¥623M | CN¥591M | CN¥542M |
| Capital expenditure | CN¥203M | CN¥232M | CN¥280M | CN¥448M | CN¥235M |
| Total debt | CN¥1.08B | CN¥1.14B | CN¥976M | CN¥736M | CN¥720M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Huaxia Eye Hospital 301267.SZ | $1.92B | -16% | +2% | 15% | 24.7× | 3.8% |
| Aier Eye Hospital 300015.SZ | $12.5B | -16% | +5% | 21% | 29.5× | 11.7% |
| Topchoice Medical 600763.SS | $2.51B | -11% | +7% | 26% | 26.7× | 13.6% |
| Sanbo Hospital Management 301293.SZ | $1.48B | -21% | +17% | 6% | 148.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301267.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | +1.8% | 11th highest of 21 |
| 6-month return | -15.8% | +2.2% | 3rd lowest of 21 |
| Distance from 52-week high | -26.2% | -15.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +2.2% | +6.9% | 5th lowest of 21 |
| Operating margin | 14.9% | 8.8% | 5th highest of 20 |
| Forward P/E | 24.7× | 38.1× | 6th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 3.8% | 13.6% | 2nd least demanding of 16 |
| Growth delivered (Del g) | +10.4% | +8.7% | 5th highest of 16 |
| Hurdle (Req g minus delivered) | -6.7 pp | +2.7 pp | 3rd least demanding of 16 |
| ROIC minus cost of capital | +13.5 pp | -2.4 pp | highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Huaxia Eye Hospital 301267.SZ | China | $1.92B | -16% | +2% | 15% | 24.7× | 3.8% | +10.4% |
| Extendicare EXE.TO | Canada | $1.87B | -9% | +31% | 9% | 19.4× | 11.2% | +8.5% |
| Brookdale Senior Living BKD | United States | $2.15B | -31% | -4% | 5% | 127.7× | 22.4% | -1.4% |
| Sienna Senior Living SIA.TO | Canada | $1.63B | -11% | +16% | 10% | 38.1× | 19.6% | +8.6% |
| Xi'an International Medical Investment 000516.SZ | China | $1.54B | 0% | -1% | -2% | n/a | 13.6% | +20.6% |
| Ardent Health ARDT | United States | $2.44B | +71% | +3% | 4% | 14.5× | 4.0% | +8.7% |
| Aevis Victoria AEVS.SW | Switzerland | $1.49B | +9% | +15% | -6% | 107.9× | 26.6% | +10.2% |
| Sanbo Hospital Management 301293.SZ | China | $1.48B | -21% | +17% | 6% | 148.9× | n/a | n/a |
| Topchoice Medical 600763.SS | China | $2.51B | -11% | +7% | 26% | 26.7× | 13.6% | +6.9% |
| Spire Healthcare SPI.L | United Kingdom | $1.34B | +68% | +2% | 8% | 19.5× | 9.8% | +11.4% |
| Rainbow Childrens Medicare RAINBOW.NS | India | $1.34B | -4% | +23% | 22% | 39.4× | 30.2% | +21.2% |
| Raffles Medical BSL.SI | Singapore | $1.25B | -15% | -3% | 11% | 27.3× | -2.4% | +6.1% |
| CVS CVSG.L | United Kingdom | $1.23B | +20% | +6% | 11% | 14.3× | 13.7% | +6.9% |
| Surgery Partners SGRY | United States | $2.99B | +61% | +4% | 14% | 62.5× | 13.8% | +12.2% |
| Park Medi World PARKHOSPS.NS | India | $1.15B | +2% | +21% | n/a | 28.3× | 30.5% | +10.2% |
| Krishna Institute of Medical Sciences KIMS.NS | India | $3.21B | +2% | +31% | 12% | 70.0× | n/a | n/a |
| National HealthCare NHC | United States | $3.27B | +11% | +7% | -8% | n/a | 7.9% | +9.7% |
| Ramsay Generale de Sante GDS.PA | France | $1.09B | -15% | +3% | 4% | n/a | 6.3% | +6.0% |
| Rhon-klinikum RHK.DE | Germany | $1.08B | +14% | +5% | 3% | 22.5× | n/a | n/a |
| Yatharth Hospital and Trauma Care Services YATHARTH.NS | India | $1.05B | +25% | +50% | 16% | 41.0× | n/a | n/a |
| Jupiter Life Line Hospitals JLHL.NS | India | $1,000M | +14% | +17% | 16% | 48.5× | n/a | n/a |